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Abstract
Background: Though the importance of the transmembrane mucin MUC1 in mammary oncogenesis has long been recog-
nized, the relative contributions of the cytoplasmic tail and tandem repeat domains are poorly understood.
Methods: To address this, mouse models of mammary carcinogenesis were created expressing full-length, cytoplasmic 
tail-deleted, or tandem repeat-deleted MUC1 constructs.
Results: Overexpression of full-length MUC1 resulted in tumor formation in young mice (12 months); however, loss of 
either the cytoplasmic tail or the tandem repeat domain abrogated this oncogenic capacity. Aged mice in all strains developed 
late-onset mammary tumors similar to those previously described for the FVB background.
Conclusions: This study is the ﬁ  rst spontaneous cancer model to address the relative importance of the cytoplasmic tail and 
tandem repeat domains to MUC1-driven mammary oncogenesis, and suggests that both of these domains are essential for 
tumor formation.
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Introduction
MUC1 is a tumor antigen and oncogene that is overexpressed in the majority (90%) of human breast 
carcinomas (Gendler, 2001). Mouse models have been integral to the current understanding of the role 
of MUC1 in the development and progression of cancer of the mammary epithelium (note that the 
human homolog is written MUC1 and the mouse Muc1). Crossing the Muc1 knockout mouse (Muc1
-/-) 
with strains expressing mouse mammary tumor virus (MMTV)-driven oncogenes suggests that Muc1 
cooperates with other tumorigenic factors in cancer: MMTV-Wnt-1 and MMTV-TGFα mice show 
signiﬁ  cantly delayed onset of tumors when on the Muc1
-/- background (Schroeder et al. 2003; Pocham-
palli et al. 2007), while MMTV-PyV MT (polyomavirus middle T antigen) mice lacking Muc1 have 
signiﬁ  cantly reduced tumor progression with a trend towards decreased metastasis (Spicer et al. 1995). 
In complement to this, MUC1 has been shown to transform rat 3Y1 ﬁ  broblasts (Li et al. 2003), and 
MMTV-MUC1 transgenic mice develop spontaneous mammary tumors, indicating that MUC1 is an 
oncogene in its own right (Schroeder et al. 2004).
It is not yet clear what regions of the MUC1 protein are most involved in tumorigenesis. MUC1 is 
expressed on the cell surface as a heterodimer, comprised of two very different subunits (Gendler, 2001). 
The larger fragment is wholly extracellular, and is comprised mainly of a variable number of tandem 
repeats (TR) rich in serines and threonines. This subunit is heavily glycosylated; the majority of the size 
and glycosylation of the extracellular fragment is provided by the TR. The glycosylation is heterogeneous 
and differs in each tissue and physiologic state of the tissue (Hollingsworth and Swanson, 2004; Hattrup 58
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and Gendler, 2007). The extracellular subunit and 
in particular the TR domain are thought to play 
important roles in modulating cellular adhesion: 
bacteria, viruses, selectins, ﬂ  agellin, and intercellular 
adhesion molecule-1 (ICAM-1) bind to the 
extracellular domain, while the enormous size and 
extended structure of MUC1 provide steric 
hindrance to cellular contact (reviewed in (Baldus 
et al. 2004; Hattrup and Gendler, 2007)).
The smaller MUC1 subunit is made up of a short 
extracellular stem, a single-pass transmembrane 
domain, and the 72-amino acid cytoplasmic tail 
(CT domain). This fragment is most notable for 
the interaction of the CT with numerous signaling 
proteins, many of which have been implicated in 
cancer (reviewed in (Singh and Hollingsworth, 
2006; Hattrup and Gendler, 2007)). Among the 
proteins known to bind to MUC1 are several of 
the src family of kinases (Li et al. 2001; Mukherjee 
et al. 2005), the erbB receptor tyrosine kinases 
(Schroeder et al. 2001; Li et al. 2001), β-catenin 
(Yamamoto et al. 1997; Schroeder et al. 2003) and 
glycogen synthase kinase 3β (Li et al. 1998). Inter-
action with these important signaling networks is 
thought to facilitate MUC1-mediated oncogenesis. 
In addition, the CT has been found in the nucleus 
in association with potent transcription factors, 
including β-catenin (Wen et al. 2003; Huang et al. 
2003), p53 (Wei et al. 2005), FOXO3a (Yin et al. 
2004), estrogen receptor α (Wei et al. 2006) and 
affects nuclear localization (Thompson et al. 2006) 
and activation (Ahmad et al. 2007) of NF-κB, 
indicating that MUC1 may alter transcription in 
addition to its effects on signaling networks.
Despite acknowledgement of their very different 
functional roles, little has been done in physiological 
settings such as animal models to discern the 
relative importance of the TR and CT domains in 
MUC1 oncogenic activity. A recent paper (Kohlgraf 
et al. 2003) highlights the importance of proper 
model systems for studying the role of MUC1: 
in vitro, deletion of either the TR or the CT resulted 
in decreased invasion of transfected pancreatic 
cancer cells as compared to cells expressing full-
length MUC1. In vivo, however, the same cells 
behaved quite differently. Those transfected with 
full-length MUC1 showed the least propensity to 
invade blood vessels and metastasize to the lymph 
nodes, while loss of either the TR or the CT restored 
the aggressive phenotype of the parental cells. 
Clearly, though much work on MUC1 function has 
been performed in cell culture, such in vitro systems 
fail to fully recapitulate the complex regulation of 
MUC1 function that is present in vivo. To further 
study the role of specific MUC1 domains in 
spontaneous mammary oncogenesis, we examined 
the effect of deleting the CT or TR domains on 
MUC1-induced tumorigenesis.
Materials and Methods
FVB mice from Jackson Laboratory were bred to 
express CT-deleted (MUC1∆CT) or TR-deleted 
(MUC1∆TR) MUC1 under the MMTV LTR pro-
moter (Schroeder et al. 2001). These strains were 
then crossed onto the Muc1
-/- knockout background 
(Spicer et al. 1995) and thus express only transgenic, 
human MUC1; crosses are called MMFK (MMTV-
MUC1 × Muc1
-/-), ∆CTK (MMTV-MUC1∆CT × 
Muc1
-/-) and ∆TRK (MMTV-MUC1∆TR × Muc1
-/-). 
The MMF mice are MMTV-MUC1 transgenics with 
endogenous Muc1. Two lines each of the various 
transgenic mice were created; both lines of MMF 
mice were originally characterized as developing 
tumors (Schroeder et al. 2004). For the purposes of 
this study, a single line of each transgenic was fol-
lowed. The Muc1
-/- mice are fully congenic with the 
FVB background, having undergone greater than 20 
backcrosses to FVB mice; the various transgenic 
mice were generated and have been continuously 
maintained in the FVB background. The number of 
mice in each group was: FVB wildtype controls 
(n = 20), Muc1
-/-controls (n = 16), MMF (n = 38), 
MMFK (n = 22), ∆CTK (n = 19), and ∆TRK (n = 17). 
As the comparison of MMF mice to FVB wildtype 
controls has already been published (Schroeder et al. 
2004), we focus here primarily on the transgenic 
mice on the Muc1
-/- background and include MMF 
results as a positive control.
Mice were permitted to breed continuously until 
6–7 months of age and were monitored for tumor 
growth. At sacriﬁ  ce (when tumors had reached 
dimensions of approximately 5–8 mm
2), pituitary 
glands, mammary glands #2/3 and #4, and all tumors 
present were ﬁ  xed in formalin; tumors and tissues 
were stained with hematoxylin and eosin and sec-
tions (mammary glands, tumors if present and 
pituitary glands) from every animal were analyzed 
by a veterinary pathologist. Tumor-free survival was 
analyzed according to the Kaplan-Meier method.
Results and Discussion
Transgenic mice expressing full-length, CT-deleted, 
and TR-deleted MUC1 under the control of the 59
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MMTV promoter have been previously described 
(Schroeder et al. 2001; Schroeder et al. 2004); 
however, earlier studies were performed using 
animals with wildtype mouse Muc1 expression, 
potentially confounding analysis of the importance 
of the domains of the human protein. For this rea-
son, the MUC1 transgenic mice were crossed onto 
the mouse Muc1
-/- background to examine the 
inﬂ  uence of the human MUC1 domains in isola-
tion. These crosses are called MMFK (expressing 
full-length human MUC1), ∆CTK (CT-deleted 
human MUC1), and ∆TRK (TR-deleted human 
MUC1), all of which lack mouse Muc1.
Mice were observed for mammary tumor forma-
tion, along with FVB (wildtype, i.e. Muc1
+/+) and 
Muc1
-/- controls. A comparison of MMF mice to 
FVB wildtype controls (i.e. overexpression of 
human MUC1 in addition to normal mouse Muc1 
levels) has already been published (Schroeder et al. 
2004), thus we focus here on the knockout crosses 
and include MMF results primarily as a positive 
control. Female mice were bred continuously for 
6–8 months and then aged for tumor formation. The 
number of mice in each group was as follows: FVB 
(n = 20), Muc1
-/-(n = 16), MMF (n = 38), MMFK 
(n = 22), ∆CTK (n = 19), and ∆TRK (n = 17).
All mice in this study were on the FVB back-
ground. Two recent studies (Wakeﬁ  eld et al. 2003; 
Nieto et al. 2003) raised concerns about use of the 
FVB mice as tumor models: by 13 months, 40% of 
virgin FVB females developed spontaneous mam-
mary hyperplasia, while 67% of multiparous ani-
mals had both mammary tumors and pituitary 
adenomas by age 18–23 months. Although it is not 
yet clear whether this phenotype is present in all 
strains of FVB mice, we were also able to detect 
late-onset mammary and pituitary abnormalities in 
our mice, starting at 13 months. As our published 
study (Schroeder et al. 2004) included mice that 
had been aged for 18 months, we felt that it was 
important to verify that MUC1 did indeed induce 
mammary gland tumors before FVB-induced 
tumors confounded the results. For this reason, data 
were analyzed both for overall survival and at age 
12 months to address the inﬂ  uence of late-onset 
mammary tumor formation in the FVB strain.
Figure 1A shows the Kaplan-Meier survival plot 
for all arms of the study through 12 months of age. 
Although no FVB or Muc1
-/- mice developed tumors 
by 12 months of age, both MMF and MMFK strains 
showed spontaneous mammary tumor formation 
within the ﬁ  rst year (Fig. 1A). The difference in 
survival between MMFK and Muc1
-/- became 
statistically signiﬁ  cant when mice were followed 
until tumor formation or morbidity (p = 0.03, Fig. 
1B), similar to the results previously reported in 
MMF mice retaining mouse Muc1(Schroeder et al. 
2004). Thus, these data conﬁ  rm that human MUC1 
overexpression in the mammary gland results in 
mammary tumorigenesis, regardless of the presence 
or absence of mouse Muc1.
Interestingly, MMFK mice develop tumors more 
slowly than do their MMF counterparts, which 
express the same full-length human transgene but 
retain mouse Muc1. Although the trend was not 
statistically signiﬁ  cant, this ﬁ  nding agrees with 
previous studies showing reduced tumor formation 
or progression in mouse mammary tumor models 
in Muc1
-/- animals (Spicer et al. 1995; Schroeder 
et al. 2003; Pochampalli et al. 2007). This suggests 
that the transgenic human MUC1 behaves similarly 
to other oncogenes, which show reduced tumori-
genic ability when mouse Muc1 is absent.
No mammary tumors were found by 12 months 
in either strain expressing domain-deleted MUC1 
(∆CTK and ∆TRK). This is despite similar expres-
sion levels of the MUC1 transgene in MMFK, 
∆CTK, and ∆TRK animals (Schroeder et al. 2001). 
These results suggest that both the adhesion-
modulating TR and cell-signaling CT domains are 
required for MUC1driven oncogenesis. The CT is 
clearly important in signal transduction; it interacts 
with a number of kinases (among them, src, EGFR, 
erbB-2,-3,-4, GSK3β, PKCδ, PI3-K), signaling 
(Grb2) and adhesion proteins (β-catenin) reviewed 
in (Singh and Hollingsworth, 2006; Hattrup and 
Gendler, 2007). Tumors from mice with 
Muc1 compared to those lacking Muc1 show 
increased β-catenin interactions, reduced apoptosis, 
decreased expression of activated ERK1/2, and 
increased association of kinases with their down-
stream signaling partners, suggesting that MUC1 
likely serves as an adaptor protein to coordinate the 
signaling activites of these oncogenic proteins (Al 
Masri and Gendler, 2005). The functional role of 
the extracellular TR domain is more difﬁ  cult to 
understand. MUC1 exists as a heterodimeric 
structure held together by non-covalent interactions. 
The functional importance of this structure is not 
clear, but presumably would enable rapid dissociation 
of the heavily glycosylated domain at the cell sur-
face, which may relay information to the cell regard-
ing conditions outside the cell. What these conditions 
are in oncogenesis remain unclear at the present 60
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Figure 1. Tumor-free survival in MUC1 transgenic mice. Tumor-free survival was plotted according to the Kaplan-Meier method for (a) all 
lines (transgenic and control), up to 12 months of age and (b) until morbidity.
A61
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time. The display of diverse carbohydrate structures 
on Muc1 likely serve to bind most bacteria, viruses 
and inhaled particles (in the case of the lung), thus 
mediating rapid clearance. The mucin domain may 
also bind growth factors, cytokines and other pro-
teins that may function in as yet undeﬁ  ned ways 
similar to what has been observed for proteoglycans 
(Mahtouk et al. 2006). An additional consideration 
may be that the altered glycosylation of the TR or 
the sloughing of the extracellular domain is involved 
in inducing tolerance or evasion of immune surveil-
lance, thus hindering early tumor growth when 
MUC1 TR expression is lost. Failure of the ∆TR 
mice to form tumors suggests an important role for 
this domain in oncogenesis. Future studies will be 
needed to deﬁ  ne this key role, which will be con-
founded by the diverse nature of the carbohydrate 
structures which are known to vary in different tis-
sues and physiological states.
Notably, when mice were permitted to age beyond 
12 months, the incidence of mammary tumors in all 
arms (including Muc1
-/- and FVB negative control 
animals) increased rapidly (Fig. 1B). Beyond the 
hyperplasia reported previously (Wakeﬁ  eld et al. 
2003), we observed frank tumors forming in the 
mammary gland beginning at 13 months (Fig. 1B). 
These tumors arose earlier than the age reported by 
Wakeﬁ  eld et al. for tumor formation in multiparous 
mice, where 4/6 (67%) mice aged 18–23 months 
were reported to develop mammary tumors. Muc1
-/- 
mice appear to develop tumors more slowly than 
FVB, although the difference is not significant 
(p = 0.16); this may reﬂ  ect a role for mouse Muc1 
in spontaneous FVB oncogenesis.
At sacriﬁ  ce, mammary and pituitary glands 
were taken from multiparous female mice, forma-
lin ﬁ  xed, and embedded for histology. The pituitary 
adenomas described by Wakeﬁ  eld et al. (2003) 
were detected in all transgenic and control lines in 
this study. Of the subset of mice (n = 97) that 
reached age 13–25 months and were able to be 
assessed for pituitary adenomas, 32 (33.0%) had 
pituitary adenomas at time of sacriﬁ  ce. This inci-
dence is notably lower than the 67% (4 of 6) 
reported by Wakeﬁ  eld et al. However, considerably 
more aged mice were included in this study 
compared to that report (n = 97 vs. n = 6); in 
addition, mice were sacriﬁ  ced earlier in this study 
(beginning at 13 months vs. beginning at 18 months) 
(Wakeﬁ  eld et al. 2003), perhaps precluding forma-
tion of frank pituitary adenomas in some mice. In 
the 97 mice examined for both pituitary and 
mammary abnormalities, the overall incidence of 
mammary tumors in aged, multiparous mice in this 
study is similar (52 of 97, 53.6%) to the 67% 
reported in Wakeﬁ  eld et al. (2003).
We noted, however, that the tumors arising in 
young (12 mo), MUC1-transgenic mice (MMF 
or MMFK) did not resemble the late-onset FVB 
tumors histologically (Fig. 2). Late-onset FVB 
tumors (Fig. 2, upper left) displayed the squamous 
metaplasia and inﬂ  ammatory inﬁ  ltrates described 
by Wakeﬁ  eld; these were absent from the MUC1-
driven tumors in young mice (Fig. 2, lower panels). 
Also visible in the FVB tumors was a characteristic 
“keratin whorl” pattern (arrows) that did not appear 
in the MUC1-driven tumors that arose prior to 12 
months of age. Of note, the tumors arising in aged 
∆CTK and ∆TRK mice more closely resembled the 
FVB tumors, with prominent keratin whorls, squa-
mous metaplasia, and inflammatory infiltrates 
(Fig. 2, upper right). Most late-onset (12 mo) 
tumors in MMF and MMFK mice also showed this 
morphological pattern (data not shown).
The characteristic histology and late onset of 
tumors arising in ∆CTK and ∆TRK mice suggests 
that these mammary tumors are related to the spon-
taneous, late-onset oncogenesis of the FVB back-
ground in aged mice. In contrast, the MMF and 
MMFK tumors arose earlier and had very different 
morphology, forming glandular and cribiform struc-
tures typical of adenocarcinoma. Together, these 
ﬁ  ndings indicate that the ∆CTK and ∆TRK strains 
do not undergo MUC1-driven oncogenesis, suggest-
ing that both of these domains are essential for its 
tumorigenic capacity in the mammary gland.
This study was the ﬁ  rst spontaneous tumor 
model to examine the inﬂ  uence of the major func-
tional domains of the MUC1 oncoprotein. In vitro 
studies and injected tumor models have provided 
contradictory evidence as to the relative impor-
tance and nature of the TR (adhesionmodulating) 
and CT (cellular signaling) functions. Given the 
wide range of potentially oncogenic factors that 
interact with the CT domain, it is not surprising to 
find that its deletion impairs MUC1-driven 
mammary tumorigenesis. However, it is somewhat 
more unexpected that the loss of the extracellular 
TR region resulted in no tumors; this suggests a 
need for further investigation into the mechanism 
by which the TR affects oncogenesis.
In summary, we report here that deletion of either 
the extracellular tandem repeats or the cytoplasmic 
tail of the MUC1 oncogene ablates MUC1-induced 62
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tumor formation in the mouse mammary gland prior 
to 12 months of age. Beyond 12 months, analysis 
of the role of MUC1 functional domains is con-
founded by the phenotype of spontaneous, late-
onset mammary tumors arising in FVB mice, which 
was previously reported and conﬁ  rmed herein using 
mice from a different source laboratory. This study 
is the ﬁ  rst to analyze the relative importance of the 
MUC1 TR and CT domains in a spontaneous tumor 
model, and suggests that both the adhesive and 
signaling functions of MUC1 are important for its 
oncogenic potential.
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